These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 32757307)

  • 21. Time interval between neoadjuvant chemoradiotherapy and surgery for oesophageal or junctional cancer: A nationwide study.
    van der Werf LR; Dikken JL; van der Willik EM; van Berge Henegouwen MI; Nieuwenhuijzen GAP; Wijnhoven BPL;
    Eur J Cancer; 2018 Mar; 91():76-85. PubMed ID: 29353163
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Surveillance Following Treatment of Esophageal Cancer.
    Bakhos CT; Acevedo E; Petrov RV; Abbas AE
    Surg Clin North Am; 2021 Jun; 101(3):499-509. PubMed ID: 34048769
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neoadjuvant chemoradiotherapy plus surgery versus active surveillance for oesophageal cancer: a stepped-wedge cluster randomised trial.
    Noordman BJ; Wijnhoven BPL; Lagarde SM; Boonstra JJ; Coene PPLO; Dekker JWT; Doukas M; van der Gaast A; Heisterkamp J; Kouwenhoven EA; Nieuwenhuijzen GAP; Pierie JEN; Rosman C; van Sandick JW; van der Sangen MJC; Sosef MN; Spaander MCW; Valkema R; van der Zaag ES; Steyerberg EW; van Lanschot JJB;
    BMC Cancer; 2018 Feb; 18(1):142. PubMed ID: 29409469
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Endoscopic biopsy and EUS for the detection of pathologic complete response after neoadjuvant chemoradiotherapy in esophageal cancer: a systematic review and meta-analysis.
    van Rossum PSN; Goense L; Meziani J; Reitsma JB; Siersema PD; Vleggaar FP; van Vulpen M; Meijer GJ; Ruurda JP; van Hillegersberg R
    Gastrointest Endosc; 2016 May; 83(5):866-79. PubMed ID: 26632523
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Esophageal carcinoma originating in the surface epithelium with immunohistochemically proven esophageal gland duct differentiation: A case report.
    Tamura H; Saiki H; Amano T; Yamamoto M; Hayashi S; Ando H; Doi R; Nishida T; Yamamoto K; Adachi S
    World J Gastroenterol; 2017 Jun; 23(21):3928-3933. PubMed ID: 28638233
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Accuracy of staging in early oesophageal cancer using high resolution endoscopy and high resolution endosonography: a comparative, prospective, and blinded trial.
    May A; Günter E; Roth F; Gossner L; Stolte M; Vieth M; Ell C
    Gut; 2004 May; 53(5):634-40. PubMed ID: 15082579
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Non-metastatic oesophageal cancer: diagnosis and treatment].
    Voeten DM; den Bakker CM; Goedegebuure RSA; Heineman DJ; Daams F; van der Peet DL
    Ned Tijdschr Geneeskd; 2019 Sep; 163():. PubMed ID: 31556490
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of biopsies in patients with residual rectal cancer following neoadjuvant chemoradiation after downsizing: can they rule out persisting cancer?
    Perez RO; Habr-Gama A; Pereira GV; Lynn PB; Alves PA; Proscurshim I; Rawet V; Gama-Rodrigues J
    Colorectal Dis; 2012 Jun; 14(6):714-20. PubMed ID: 22568644
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of neoadjuvant chemoradiotherapy in clinical T2N0M0 esophageal cancer: A population-based cohort study.
    Goense L; Visser E; Haj Mohammad N; Mook S; Verhoeven RHA; Meijer GJ; van Rossum PSN; Ruurda JP; van Hillegersberg R
    Eur J Surg Oncol; 2018 May; 44(5):620-625. PubMed ID: 29478739
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pre-treatment maximal oesophageal wall thickness is independently associated with response to chemoradiotherapy in patients with T3-4 oesophageal squamous cell carcinoma.
    Li SH; Rau KM; Lu HI; Wang YM; Tien WY; Liang JL; Lin WC
    Eur J Cardiothorac Surg; 2012 Dec; 42(6):958-64. PubMed ID: 22466694
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A prospective cohort study on active surveillance after neoadjuvant chemoradiotherapy for esophageal cancer: protocol of Surgery As Needed for Oesophageal cancer-2.
    van der Zijden CJ; Lagarde SM; Hermus M; Kranenburg LW; van Lanschot JJB; Mostert B; Nuyttens JJME; Oudijk L; van der Sluis PC; Spaander MCW; Valkema MJ; Valkema R; Wijnhoven BPL;
    BMC Cancer; 2023 Apr; 23(1):327. PubMed ID: 37038138
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metabolomic and BH3 profiling of esophageal cancers: novel assessment methods for precision therapy.
    Taylor Ripley R; Surman DR; Diggs LP; Trepel JB; Lee MJ; Ryan J; Davis JL; Steinberg SM; Hernandez JM; Hoang C; Kenney CM; Bond CD; Kunst TF; Letai A; Schrump DS
    BMC Gastroenterol; 2018 Jun; 18(1):94. PubMed ID: 29933761
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development of a nomogram for the prediction of pathological complete response after neoadjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma.
    Chao YK; Chang HK; Tseng CK; Liu YH; Wen YW
    Dis Esophagus; 2017 Feb; 30(2):1-8. PubMed ID: 27868287
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neoadjuvant chemoradiation for patients with advanced oesophageal cancer - which response grading system best impacts prognostic discrimination?
    Puetz K; Bollschweiler E; Semrau R; Mönig SP; Hölscher AH; Drebber U
    Histopathology; 2019 Apr; 74(5):731-743. PubMed ID: 30636069
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Residual esophageal cancer after neoadjuvant chemoradiotherapy: frequently the mucosa and submucosa are involved].
    Brink F; Jähne J
    Chirurg; 2014 Mar; 85(3):257. PubMed ID: 24519613
    [No Abstract]   [Full Text] [Related]  

  • 36. Residual Esophageal Cancer After Neoadjuvant Chemoradiotherapy Frequently Involves the Mucosa and Submucosa.
    van Rossum PSN; van Hillegersberg R; Meijer GJ; Ruurda JP
    Ann Surg; 2015 Aug; 262(2):e83-4. PubMed ID: 24743619
    [No Abstract]   [Full Text] [Related]  

  • 37. [Histological classification: evaluation of resection specimens of EMR/ESD--response evaluation after neoadjuvant therapy].
    Munding J; Ziebarth W; Belyaev O; Uhl W; Tannapfel A
    Zentralbl Chir; 2013 Dec; 138 Suppl 2():e55-62. PubMed ID: 22025359
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reply to Letter: "Residual Esophageal Cancer After Neoadjuvant Chemoradiotherapy Frequently Involves the Mucosa and Submucosa".
    Shapiro J; Wijnhoven BP; van Lanschot JJ
    Ann Surg; 2015 Aug; 262(2):e84-5. PubMed ID: 24743617
    [No Abstract]   [Full Text] [Related]  

  • 39. Changes in tumour expression of programmed death-ligand 1 after neoadjuvant concurrent chemoradiotherapy in patients with squamous oesophageal cancer.
    Lim SH; Hong M; Ahn S; Choi YL; Kim KM; Oh D; Ahn YC; Jung SH; Ahn MJ; Park K; Zo JI; Shim YM; Sun JM
    Eur J Cancer; 2016 Jan; 52():1-9. PubMed ID: 26623522
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Histopathologic Features are more Important Prognostic Factors than Primary Tumour Location in Gastro-oesophageal Adenocarcinoma Treated with Preoperative Chemoradiation and Surgery.
    Vošmik M; Laco J; Sirák I; Dvořák J; Lochman P; Hodek M; Malá P; Rejchrt S; Repák R; Leško M; Ferko A; Ryška A; Melichar B; Petera J
    Pathol Oncol Res; 2018 Apr; 24(2):373-383. PubMed ID: 28550507
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.